Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Breast cancer quantitative proteome and proteogenomic landscape.

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF, Schlichting E, Naume B; Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders T, Borgen E, Kristensen VN, Russnes HG, Lingjærde OC, Mills GB, Sahlberg KK, Børresen-Dale AL, Lehtiö J.

Nat Commun. 2019 Apr 8;10(1):1600. doi: 10.1038/s41467-019-09018-y.

2.

Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM.

Cancer Immunol Res. 2019 May;7(5):701-706. doi: 10.1158/2326-6066.CIR-18-0777. Epub 2019 Feb 25.

PMID:
30804006
3.

Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P.

Nat Commun. 2019 Jan 28;10(1):525. doi: 10.1038/s41467-019-08512-7.

4.

Microvessel density in breast cancer: the impact of field area on prognostic informativeness.

Kraby MR, Opdahl S, Russnes HG, Bofin AM.

J Clin Pathol. 2019 Apr;72(4):304-310. doi: 10.1136/jclinpath-2018-205536. Epub 2019 Jan 10.

PMID:
30630872
5.

Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P.

Nat Commun. 2018 Dec 17;9(1):5397. doi: 10.1038/s41467-018-07842-2.

6.

Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers.

Glodzik D, Purdie C, Rye IH, Simpson PT, Staaf J, Span PN, Russnes HG, Nik-Zainal S.

Ann Oncol. 2018 Nov 1;29(11):2223-2231. doi: 10.1093/annonc/mdy404.

7.

Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.

Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG.

Mol Oncol. 2018 Nov;12(11):1838-1855. doi: 10.1002/1878-0261.12375. Epub 2018 Sep 21.

8.

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B.

Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

9.

Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P.

Nat Commun. 2017 Oct 31;8(1):1221. doi: 10.1038/s41467-017-01355-0. Erratum in: Nat Commun. 2018 Dec 17;9(1):5397. Nat Commun. 2019 Jan 28;10(1):525.

10.

AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth.

Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S.

Mol Cancer Ther. 2018 Jan;17(1):254-263. doi: 10.1158/1535-7163.MCT-16-0868. Epub 2017 Oct 20.

11.

Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program.

Ellingjord-Dale M, Vos L, Hjerkind KV, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1736-1744. doi: 10.1158/1055-9965.EPI-17-0611. Epub 2017 Sep 6.

12.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

13.

Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters.

Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C.

Am J Pathol. 2017 Oct;187(10):2152-2162. doi: 10.1016/j.ajpath.2017.04.022. Epub 2017 Jul 19. Review.

PMID:
28733194
14.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.

Cancer Discov. 2017 Oct;7(10):1098-1115. doi: 10.1158/2159-8290.CD-17-0222. Epub 2017 Jun 26.

15.

Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD.

Mol Oncol. 2015 Apr;9(4):861-76. doi: 10.1016/j.molonc.2014.12.013. Epub 2015 Jan 14.

16.

Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors.

Rye IH, Lundin P, Månér S, Fjelldal R, Naume B, Wigler M, Hicks J, Børresen-Dale AL, Zetterberg A, Russnes HG.

Genes Chromosomes Cancer. 2015 Apr;54(4):235-48. doi: 10.1002/gcc.22237. Epub 2014 Dec 26.

17.

eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN.

Russnes HG, Caldas C.

EMBO Mol Med. 2014 Dec;6(12):1512-4. doi: 10.15252/emmm.201404683.

18.

The multitude of molecular analyses in cancer: the opening of Pandora’s box.

Russnes HG, Lønning PE, Børresen-Dale AL, Lingjærde OC.

Genome Biol. 2014;15(9):447.

19.

GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images.

Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F.

Genome Biol. 2014 Aug 26;15(8):442. doi: 10.1186/s13059-014-0442-y.

20.

JARID1B is a luminal lineage-driving oncogene in breast cancer.

Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, Bessarabova M, Rueda OM, Nikolsky Y, Caldas C, Liu XS, Polyak K.

Cancer Cell. 2014 Jun 16;25(6):762-77. doi: 10.1016/j.ccr.2014.04.024.

21.

Nuclear CSPP1 expression defined subtypes of basal-like breast cancer.

Sternemalm J, Russnes HG, Zhao X, Risberg B, Nord S, Caldas C, Børresen-Dale AL, Stokke T, Patzke S.

Br J Cancer. 2014 Jul 15;111(2):326-38. doi: 10.1038/bjc.2014.297. Epub 2014 Jun 5.

22.

Principles and methods of integrative genomic analyses in cancer.

Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL.

Nat Rev Cancer. 2014 May;14(5):299-313. doi: 10.1038/nrc3721. Review.

PMID:
24759209
23.

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.

Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL.

BMC Cancer. 2014 Mar 19;14:211. doi: 10.1186/1471-2407-14-211.

24.

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K.

Cell Rep. 2014 Feb 13;6(3):514-27. doi: 10.1016/j.celrep.2013.12.041. Epub 2014 Jan 23.

25.

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V.

Cancer Res. 2013 Nov 1;73(21):6424-34. doi: 10.1158/0008-5472.CAN-12-4573. Epub 2013 Sep 12.

26.

Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.

Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J, Friend SH, Stolovitzky G, Aparicio S, Caldas C, Børresen-Dale AL.

Sci Transl Med. 2013 Apr 17;5(181):181re1. doi: 10.1126/scitranslmed.3006112.

27.

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B.

Acta Oncol. 2013 Jan;52(1):91-101. doi: 10.3109/0284186X.2012.713508. Epub 2012 Aug 30.

PMID:
22934555
28.

Insight into the heterogeneity of breast cancer through next-generation sequencing.

Russnes HG, Navin N, Hicks J, Borresen-Dale AL.

J Clin Invest. 2011 Oct;121(10):3810-8. doi: 10.1172/JCI57088. Epub 2011 Oct 3. Review.

29.

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B.

Breast Cancer Res. 2011 Jun 14;13(3):R61. doi: 10.1186/bcr2898.

30.

Paired distribution of molecular subtypes in bilateral breast carcinomas.

Russnes HG, Kuligina ESh, Suspitsin EN, Voskresenskiy DA, Jordanova ES, Cornelisse CJ, Borresen-Dale AL, Imyanitov EN.

Cancer Genet. 2011 Feb;204(2):96-102. doi: 10.1016/j.cancergencyto.2010.09.012.

PMID:
21504707
31.

miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.

Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL.

PLoS One. 2011 Feb 22;6(2):e16915. doi: 10.1371/journal.pone.0016915.

32.

Allele-specific copy number analysis of tumors.

Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5. doi: 10.1073/pnas.1009843107. Epub 2010 Sep 13.

33.

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL.

Sci Transl Med. 2010 Jun 30;2(38):38ra47. doi: 10.1126/scitranslmed.3000611.

34.

Triple-negative breast cancer: present challenges and new perspectives.

Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium.

Mol Oncol. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24. Review.

35.

EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors.

Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, Børresen-Dale AL, Pilpel Y, Yakhini Z, Segal E, Yarden Y.

Sci Signal. 2010 Jun 1;3(124):ra43. doi: 10.1126/scisignal.2000876.

36.

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O.

Mol Oncol. 2009 Dec;3(5-6):469-82. doi: 10.1016/j.molonc.2009.07.003. Epub 2009 Aug 4.

37.

Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL.

J Pathol. 2008 Feb;214(3):357-67.

PMID:
18044827
38.

Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T.

Mol Oncol. 2007 Sep;1(2):160-71. doi: 10.1016/j.molonc.2007.03.004. Epub 2007 Apr 4. Erratum in: Mol Oncol. 2010 Apr;4(2):169.

Supplemental Content

Loading ...
Support Center